Catalent climbs on Q4 results beat
29/08/2024 14:10
** Shares of contract drug manufacturer Catalent CTLT.N
rise 1.1% to $60.48 premarket
** Company reports Q4 adj profit of 65 cents/shr vs
analysts' average estimate of 47 cents/shr - LSEG
** CTLT's quarterly revenue of $1.3 bln beats analysts'
average expectation of $1.22 bln
** Its biologics segment recorded revenue of $605 mln,
compared to the average estimate of $502.97 mln
** Up to last close, stock up 33.1% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on Catalent
See all newsBrief: Novo Holdings Completes Acquisition Of Catalent
Novo Nordisk rises as Catalent deal in US nears
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Brief: Catalent And Novo Holdings Fulfill All Regulatory Closing Conditions For Pending Transaction
Brief: Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled